Proposed and Completed Offers, Acquisitions, Stock Updates, and Financial Results - Analyst Notes on HCA, Tenet, UHS, Chemed,

  Proposed and Completed Offers, Acquisitions, Stock Updates, and Financial
         Results - Analyst Notes on HCA, Tenet, UHS, Chemed, and EVHC

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, March 17, 2014

NEW YORK, March 17, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding HCA Holdings
Inc. (NYSE:HCA), Tenet Healthcare Corp (NYSE:THC), Universal Health Services,
Inc. (NYSE:UHS), Chemed Corporation (NYSE:CHE), and Envision Healthcare
Holdings Inc. (NYSE:EVHC). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings are
available at:


On March 3, 2014, HCA Holdings Inc. (HCA) announced that its wholly owned
subsidiary, HCA Inc., proposes to offer $3 billion aggregate principal amount
of senior secured notes, subject to market and other considerations. HCA
informed that the actual terms of the notes will depend on the market
conditions at the time of pricing. The Company stated that net proceeds from
this offering will be used by its subsidiary to redeem and repurchase the
entire $1.5 billion aggregate principal amount outstanding of 8½% senior
secured notes due 2019, and all of the $1.25 billion aggregate principal
amount outstanding of 7⅞% senior secured notes due 2020, apart from paying
related fees and general corporate purposes. The full analyst notes on HCA
Holdings Inc. are available to download free of charge at:


On March 10, 2014, Tenet Healthcare Corp (Tenet) announced that it has
successfully completed the previously announced private offering of $600
million aggregate principal amount of 5.00% senior notes due 2019. Tenet
stated thatproceeds from the offering will be used for general corporate
expenses,which includesrepayment of indebtedness and drawings under the
Company's senior secured revolving credit facility, as well as related
transaction fees and expenses. The full analyst notes on Tenet Healthcare Corp
are available to download free of charge at:


On March 3, 2014, Universal Health Services, Inc. (UHS) announced the
completion of the acquisition of Palo Verde Behavioral Health (Palo Verde)
from Tucson Medical Center. UHS stated that the acquisition establishes its
presence in the Tucson market and expands its behavioral health presence in
Arizona which includes Valley Hospital, an acute inpatient psychiatric
hospital and Calvary Addiction Recovery Center, both located in Phoenix. The
Company stated that it has also acquired a 67,324 square foot medical building
in Phoenix which will beconverted into a psychiatric hospital. UHS added that
Quail Run Behavioral Health in north Phoenixwill operate 100 inpatient
psychiatric beds and is expected to open in the fall of 2014. The full analyst
notes on Universal Health Services, Inc. are available to download free of
charge at:


On March 10, 2014, shares of Chemed Corporation's (Chemed) stock rose 0.51% to
close at $86.44. Over the previous three-day trading session, Chemed's stock
went up by2.09% while the Dow Jones Industrial Average gained 0.36% over that
same period. The full analyst notes on Chemed Corporation are available to
download free of charge at:


On March 5, 2014, Envision Healthcare Holdings Inc (EVHC) released its Q4 2013
and full-year 2013 financial results. Net revenues for Q4 2013 grew 13.0% YoY
to $984.8 million; full-year 2013 revenues also grew 13.0% YoY to $3.7
billion. EVHC generated net income attributable to the Company of $7.9 million
in Q4 2013 compared to $12.3 million Q4 2012. The Company stated that the
decrease in net income was mainly due to the tax-effected impact of $38.7
million in costs related to the partial redemption of the 8.125% Senior Notes
due 2019 (2019 Notes) on December 30, 2013, partially offset by lower interest
expense due to debt reduction from IPO proceeds in August 2013. EVCH's
full-year 2013 net income attributable to the Companywasc.$6 million, compared
to $41.2 million in full-year 2012. According to the Company, net income for
full year 2013 was affected by $88.4 million from the IPO-Related Costs in Q3
2013, along with the early redemption costs for the PIK Notes and 2019 Notes.
Further, EVCH stated thatit is reaffirming its previously announced full-year
2014 guidance with Adjusted EPS of $1.10 to $1.15 and Adjusted EBITDA of $538
million to $545 million. The full analyst notes on Envision Healthcare
Holdings Inc are available to download free of charge at:


We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.



  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
  oForanyurgentconcernsorinquiries, please contact us at compliance
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at] for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.


Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.


Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA

SOURCE Analysts Review

Contact: Contact: Adam Redford, +852-8191-3972
Press spacebar to pause and continue. Press esc to stop.